^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BNT142

i
Other names: BNT142, BNT 142, BNT-142
Associations
Company:
BioNTech
Drug class:
CD3 agonist, CLDN6 inhibitor
Related drugs:
Associations
6ms
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6. (PubMed, Sci Transl Med)
No signs of adverse effects from BNT142 RNA-LNP administration were observed in mice or cynomolgus monkeys. On the basis of these and other findings, a phase 1/2 first-in-human clinical trial has been initiated to assess the safety and preliminary efficacy of BNT142 RNA-LNP in patients with CLDN6-positive advanced solid tumors (NCT05262530).
PK/PD data • Preclinical • Journal
|
CLDN6 (Claudin 6)
|
CLDN6 positive
|
BNT142
11ms
Trial completion date • Trial primary completion date • Metastases
|
CLDN6 (Claudin 6)
|
CLDN6 positive
|
BNT142
over1year
P1/2 data • Clinical
|
CLDN6 (Claudin 6)
|
CLDN6 positive
|
BNT142
almost2years
Enrollment change
|
CLDN6 (Claudin 6)
|
CLDN6 positive
|
BNT142
over2years
Enrollment open
|
CLDN6 (Claudin 6)
|
CLDN6 positive
|
BNT142
over2years
New P1/2 trial
|
CLDN6 (Claudin 6)
|
CLDN6 positive
|
BNT142